Cellectis S.A. (CLLS)
CLLS Stock Price Chart
Explore Cellectis S.A. interactive price chart. Choose custom timeframes to analyze CLLS price movements and trends.
CLLS Company Profile
Discover essential business fundamentals and corporate details for Cellectis S.A. (CLLS) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Mar 2015
Employees
216.00
Website
https://www.cellectis.comCEO
Andre Choulika
Description
Cellectis S.A. is a biotechnology firm in the clinical development stage, concentrating on the creation of immuno-oncology therapies. These therapies harness gene-edited T-cells engineered to express chimeric antigen receptors, designed to specifically identify and eliminate malignant cells. Its operations are divided into two distinct divisions: Therapeutics and Plants. The therapeutic pipeline includes several product candidates currently undergoing development. Among these is UCART19, an allogeneic T-cell therapy targeting CD19-expressing blood cancers such as acute lymphoblastic leukemia. Other key developments encompass ALLO-501 and ALLO-501A, designed for diffuse large B-cell lymphoma and follicular lymphoma in relapsed or refractory patients; ALLO-316, intended for Renal Cell Carcinoma; UCART123 for acute myeloid leukemia; and UCART22 for B-cell acute lymphoblastic leukemia. Furthermore, UCARTCS1 and ALLO-715 are being developed to combat multiple myeloma. Strategic partnerships form a crucial part of its operations, encompassing alliances with entities such as Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. The firm also maintains a dedicated research and development collaboration with Cytovia Therapeutics, Inc. Established in 1999, Cellectis S.A. maintains its principal offices in Paris, France.
CLLS Financial Timeline
Browse a chronological timeline of Cellectis S.A. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 11 Aug 2026
EPS estimate is -$0.26, while revenue estimate is $11.05m.
Earnings released on 11 May 2026
EPS came in at -$0.18 surpassing the estimated -$0.26 by +30.32%, while revenue for the quarter reached $7.55m , missing expectations by -31.63%.
Earnings released on 19 Mar 2026
EPS came in at -$0.26 falling short of the estimated -$0.20 by -27.87%, while revenue for the quarter reached $12.20m , missing expectations by -8.87%.
Earnings released on 7 Nov 2025
EPS came in at $0.01 surpassing the estimated -$0.10 by +110.00%, while revenue for the quarter reached $35.17m , beating expectations by +242.39%.
Earnings released on 4 Aug 2025
EPS came in at -$0.24 falling short of the estimated -$0.10 by -140.00%, while revenue for the quarter reached $16.94m , beating expectations by +106.00%.
Earnings released on 12 May 2025
EPS came in at -$0.18 surpassing the estimated -$0.19 by +5.26%, while revenue for the quarter reached $10.66m , missing expectations by -16.18%.
Earnings released on 13 Mar 2025
EPS came in at -$0.16 falling short of the estimated $0.06 by -366.67%, while revenue for the quarter reached $12.72m , beating expectations by +38.68%.
Earnings released on 4 Nov 2024
EPS came in at -$0.23 falling short of the estimated -$0.20 by -15.00%, while revenue for the quarter reached $16.20m , missing expectations by -20.65%.
Earnings released on 6 Aug 2024
EPS came in at -$0.28 surpassing the estimated -$0.33 by +15.15%, while revenue for the quarter reached $8.06m , beating expectations by +132.31%.
Earnings released on 29 Apr 2024
EPS came in at -$0.64 falling short of the estimated -$0.33 by -93.94%, while revenue for the quarter reached $4.53m , beating expectations by +30.49%.
Earnings released on 13 Mar 2024
EPS came in at -$0.70 falling short of the estimated -$0.22 by -218.18%, while revenue for the quarter reached $283.00k , missing expectations by -83.81%.
Earnings released on 6 Nov 2023
EPS came in at -$0.31 surpassing the estimated -$0.36 by +13.89%, while revenue for the quarter reached $155.00k , missing expectations by -95.42%.
Earnings released on 3 Aug 2023
EPS came in at -$0.14 surpassing the estimated -$0.38 by +63.16%, while revenue for the quarter reached $178.00k , missing expectations by -96.02%.
Earnings released on 4 May 2023
EPS came in at -$0.58 falling short of the estimated -$0.30 by -93.33%, while revenue for the quarter reached $139.00k , missing expectations by -97.68%.
Earnings released on 8 Mar 2023
EPS came in at -$0.57 surpassing the estimated -$0.75 by +24.00%, while revenue for the quarter reached $16.02m , missing expectations by -13.76%.
Earnings released on 3 Nov 2022
EPS came in at -$0.63 falling short of the estimated -$0.58 by -8.62%, while revenue for the quarter reached $217.00k , missing expectations by -98.71%.
Earnings released on 4 Aug 2022
EPS came in at -$0.42 surpassing the estimated -$0.73 by +42.47%, while revenue for the quarter reached $1.35m , missing expectations by -94.25%.
Earnings released on 12 May 2022
EPS came in at -$0.70 falling short of the estimated -$0.62 by -12.90%, while revenue for the quarter reached $1.70m , missing expectations by -90.88%.
Earnings released on 3 Mar 2022
EPS came in at -$0.55 surpassing the estimated -$1.05 by +47.62%, while revenue for the quarter reached $13.65m , beating expectations by +38.44%.
Earnings released on 4 Nov 2021
EPS came in at -$0.82 matching the estimated -$0.82, while revenue for the quarter reached $8.31m , missing expectations by -27.28%.
Earnings released on 5 Aug 2021
EPS came in at -$0.88 falling short of the estimated -$0.75 by -17.33%, while revenue for the quarter reached $11.18m , missing expectations by -23.53%.
CLLS Stock Performance
Access detailed CLLS performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
